Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Antibodies to Cytokine Protect Eyes During Bacterial Infection

By BiotechDaily International staff writers
Posted on 31 Oct 2012
Study shows improved pathology of bacterial eye infection upon topical treatment with polyclonal antibodies against the main neutrophil recruiting, proinflammatory cytokine; surprisingly, bacterial clearance was also improved.

Severe tissue damage during bacterial infections is often largely caused by inflammatory immune system by-products, noxious substances released from neutrophils attracted to the infection site to clear away the pathogen. As a key to attracting neutrophils, the proinflammatory cytokine interleukin-17 (IL-17) contributes to both microbial clearance as well as to inflammation-associated tissue damage.

A study led by researchers at Brigham and Women’s Hospital (Boston, MA, USA) investigated in vivo roles of IL-17 in mammalian eye infections using Pseudomonas aeruginosa to cause ulcerative keratitis after scratch injury in a mouse model. Two experimental approaches were used: examination of IL-17 receptor (IL-17R) deficient mice and testing of a topical treatment with polyclonal antibodies against IL-17. Pseudomonas aeruginosa was chosen mainly due to it being a common cause of corneal infections (particularly in those at higher risk such as extended-wear contact lens users) and as it is often found to be resistant to antibiotics.

The findings, published in the journal Infection and Immunity, October 2012, from both approaches showed that neutralization of IL-17 during P. aeruginosa corneal infection reduces neutrophil influx and pathology without compromising bacterial clearance. The antibody-mediated IL-17 neutralization approach was tested with six different laboratory or clinical P. aeruginosa strains, including both invasive and cytotoxic strains, all of which gave essentially the same results.

The strategy of inhibiting neutrophil tissue infiltration risked reducing the immune system’s bacteria-killing function - “We thought that blocking IL-17 infection might worsen eye infections,” said principal investigator Prof. Gregory P. Priebe of Brigham and Women’s Hospital and Boston Children’s Hospital, “Surprisingly, just the opposite was seen: blocking IL-17 with antibodies led both to fewer neutrophils in the eye, and to fewer bacteria.” The results therefore offer a new avenue for therapy of these sight-threatening infections.

Related Links:
Brigham and Women’s Hospital


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: To adhere to catheters and start urinary tract infections, bacteria extend microscopic fibers with sticky proteins at their ends. Researchers have developed a vaccine that blocks the EbpA protein, visible as a white bulge above, and stops infections in mice (Photo courtesy of Dr. John Heuser, Washington University School of Medicine).

Blocking Binding of Bacteria to Fibrinogen Prevents Biofilm Formation and Catheter-Associated Bladder Infection in Mice

A team of molecular microbiologists has identified and targeted a critical step in biofilm formation and developed a vaccine that prevents catheter-associated urinary tract infections in mice.... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.